Serum Levels of B-Cell Activating Factor of TNF Family (BAFF) as a Useful Indicator for the Activity of Graves’ Disease

Sumito Sunagawa, Tsuyoshi Kouki, Shin-ichiro Taira, Rei Ueda, Kouichi Yabiku, Tomomi Ikema, Ayako Nakachi, Chisayo Kozuka, Moritake Higa, Ken Yamakawa, Michio Shimabukuro, Hiroaki Masuzaki

Abstract


Background: Graves’ disease (GD) is a thyroid-specific autoimmune disorder. Both B-cell activating factor of TNF family (BAFF) and a proliferation-inducing ligand (APRIL) are cytokines which share a role for regulating survival and proliferation of B lymphocytes. Elevated level of these cytokines in circulation was observed in several types of autoimmune diseases. However, there were no reports focusing on the potential relationship between BAFF and the activity of GD. To explore the pathophysiologic role of BAFF and APRIL in GD, we investigated serum levels of BAFF and APRIL in patients with GD.

Methods: We enrolled twenty three patients newly diagnosed as GD and twenty healthy donors as controls. We measured serum levels of BAFF and APRIL in patients and controls by ELISA.

Results: Serum level of BAFF was significantly elevated in patients with GD compared to controls (1329 + 435 pg/mL vs. 983 + 308 pg/mL, P < 0.01). Notably, serum BAFF level was significantly correlated with free-T3 to free-T4 ratio (FT3/FT4), a useful indicator for the disease activity of GD.

Conclusions: Findings in the present study offer a novel opportunity to evaluate GD.




 doi:10.4021/jem16w


Keywords


Cytokine; BAFF; APRIL; Graves’ disease; Autoimmunity; Free T3 to free T4 ratio

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.        
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!